Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028
NEW YORK, March 6, 2020 /PRNewswire/ --
Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028
Summary
Read the full report: https://www.reportlinker.com/p05872291/?utm_source=PRN
Onychomycosis (tinea unguium) of the toenail is a fungal infection of the nail by dermatophytic, nondermatophytic, or yeast species.Infection can occur in the nail matrix, nail bed, or nail plate.
While dermatophytic onychomycosis (DO) is not considered life-threatening, it can cause discomfort, pain, and physical and occupational limitations. Onychomycosis patients can be identified as having thick or brittle nails, along with discoloration (white and opaque) and inflammation of the skin underneath the nail.
The analyst estimates that sales of drugs in the US DO market were approximately $208.8M in 2018, not taking into account over-the-counter (OTC) treatments for the disease. As one of the largest onychomycosis markets in the world, the US is expected to see the market grow to $676.5M by 2028, at a Compound Annual Growth Rate (CAGR) of 12.5% from 2018-2028. This growth will be mainly driven by the launche of several new topical therapies. However, the analyst expects the patents of Jublia and Kerydin, the only branded marketed products, to expire over the forecast and thus face generic competition.
The DO pipeline consists entirely of topicals, accounting for the moderate growth of the market over the next ten years. The three pipeline agents are Moberg Pharma's MOB-015, Blueberry therapeutics' BB2603-om, and Hallux Inc.'s HTS-519
Key Highlights
- epidemiology team forecast an increasing prevalence of DO, representing one of the main drivers for market growth.
- Pipeline topical agents need to demonstrate efficacy on par with oral treatments through novel mechanisms of action.
- Highly efficacious, yet safe therapy remains the highest unmet need of DO treatment.
- Opportunities are expected in patients who prefer topical treatments in order to avoid any side effects and prevent drug-drug interactions with other medications.
Key Questions Answered
- What are the key drivers behind the increasing uptake of both oral and topical DO drugs, and which drug class is expected to see greater gains over the forecast period?
- When will the key patents of Jublia and Kerydin expire, and how will it affect drug sales and the overall DO market in the US?
- What are the struggles for pipeline drug development in the DO market? Why does the analyst expect the pipeline drugs to have a substantial impact on the marketspace during the forecast period?
Scope
- Overview of DO, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized DO therapeutics market revenue, cost of therapy per patient, and treatment usage patterns, with the forecast covering 2018 to 2028.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DO therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DO therapy.
- Analysis of the current and future market competition in the US DO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the US therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US DO therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: https://www.reportlinker.com/p05872291/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article